PAR : OSE.PA

OSE Immunotherapeutics S.A.

$3.16 EUR

-$0.04 (-1.25%)

Volume
78.56K
Average Volume
277.94K
Market Capitalization
$74.32M
P/E Ratio
-1.87
Dividend Yield
0.00%
Price Target
Year High
$7.70
Year Low
$2.87
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.28
Company Overview

PAR

Marc Le Bozec

Biotechnology

Healthcare

OSE.PA

64

FR

EUR

https://www.ose-immuno.com

33 2 28 29 10 10

F6913C100

N/A

Liquidity Metrics

1.29

1.28

1.28

0.71

0.00

Sales & Valuation

$2.62M

28.38

2.59

-2.18

-1.52

Profitability

-$1.69

-$37.7M

-1439.48%

-1605.73%

-96.73%

-48.06%

P/E Metrics

-1.87

0.01

0.01

Analyst Price Target & Rating

Strong Sell

1/5

0 Analysts

%

Financial Health Scores

0.65

4/9

$7.09M

$78.44M

$51.1M

-$10.23M

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Sonya Montgomery Chief Development Officer
Bérangère Vasseur Chief Medical Officer Immuno-Oncology
Alain Chatelin Medical Director
Silvia Comis Chief Clinical & Medical Research Officer
Jean-Jacques Mention Chief Business Officer
Julien Perrier Chief Commercial Officer
Marc Le Bozec Chief Executive Officer & Director
Thomas Gidoin Deputy CEO & CFO
Anne-Laure Autret-Cornet Administrative & Financial Director and Employee Shareholder Representative Director
Aurore Morello Chief Scientific Officer
Linda Lebon Chief Regulatory Officer
Poll Results

No votes yet today — be the first to share your view!

About OSE Immunotherapeutics S.A. (PAR:OSE.PA) Stock

Based in Nantes, France, OSE Immunotherapeutics S.A. specializes in creating immunotherapies designed to activate or regulate the immune system. Their work primarily targets both immuno-oncology and autoimmune diseases. Their advanced pipeline features Tedopi, which is currently in Phase III clinical trials for non-small cell lung cancer, with further Phase II investigations ongoing for pancreatic and ovarian cancers. For infectious diseases, they are developing CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus. In oncology, their portfolio also includes BI 765063, in Phase I for solid tumors, and BiCKI, an innovative bispecific checkpoint inhibitor platform. BiCKI is engineered to counteract cancer's primary and secondary resistance mechanisms by targeting PD-1 alongside other ... novel pathways. Addressing autoimmune and inflammatory conditions, OSE Immunotherapeutics is progressing OSE-127, a humanized monoclonal antibody in Phase II trials for both ulcerative colitis and Sjögren's Syndrome. FR104 is undergoing Phase I development for rheumatoid arthritis, while OSE-230, an agonist antibody against ChemR23, aims to resolve chronic inflammation. The company maintains strategic collaborations and partnerships with organizations such as GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. OSE Immunotherapeutics S.A. was formerly known as OSE Pharma SA until its name change in May 2016.

Frequently Asked Questions

What is the current OSE Immunotherapeutics S.A. (OSE.PA) stock price?

OSE Immunotherapeutics S.A.(PAR:OSE.PA) stock price is $3.16 in the last trading session. During the trading session, OSE.PA stock reached the peak price of $7.7 while $2.872 was the lowest point it dropped to. The percentage change in OSE.PA stock occurred in the recent session was --1.25% while the dollar amount for the price change in OSE.PA stock was -$0.04.

OSE.PA's industry and sector of operation?

The PAR listed OSE.PA is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of OSE.PA?

Sonya Montgomery | Chief Development Officer
Bérangère Vasseur | Chief Medical Officer Immuno-Oncology
Alain Chatelin | Medical Director
Silvia Comis | Chief Clinical & Medical Research Officer
Jean-Jacques Mention | Chief Business Officer

How many employees does OSE.PA have?

Number of OSE.PA employees currently stands at 64. OSE.PA operates from 22, boulevard Benoni Goullin, Nantes, PL 44200, FR.

Link for OSE.PA official website?

Official Website of OSE.PA is: https://www.ose-immuno.com

How do I contact OSE.PA?

OSE.PA could be contacted at phone #33 2 28 29 10 10 and can also be accessed through its website. OSE.PA operates from 22, boulevard Benoni Goullin, Nantes, PL 44200, FR.

How many shares of OSE.PA are traded daily?

The average number of OSE.PA shares traded daily for last 3 months was 277.94K.

What is the market cap of OSE.PA currently?

The market value of OSE.PA currently stands at $74.32M with its latest stock price at $3.16